Advertisement
AXON vs PGEN
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AXON is a Hold and PGEN is a Hold.
AXON in -1.45% downward trend, sliding for three consecutive days on October 14, 2026
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where AXON declined for three days, in 201 of 288 cases, the price declined further within the following month. The odds of a continued downward trend are 70%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Aroon Indicator for AXON entered a downward trend on October 16, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator entered the oversold zone -- be on the watch for AXON's price rising or consolidating in the future. That's also the time to consider buying the stock or exploring call options.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 47 of 56 cases where AXON's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 84%.
The Moving Average Convergence Divergence (MACD) for AXON just turned positive on October 06, 2026. Looking at past instances where AXON's MACD turned positive, the stock continued to rise in 27 of 38 cases over the following month. The odds of a continued upward trend are 71%.
Following a +4.16% 3-day Advance, the price is estimated to grow further. Considering data from situations where AXON advanced for three days, in 276 of 371 cases, the price rose further within the following month. The odds of a continued upward trend are 74%.
AXON may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 41 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 64 (best 1 - 100 worst), indicating steady price growth. AXON’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 72 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AXON’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 77, placing this stock better than average.
The Tickeron SMR rating for this company is 81 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 92 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (8.469) is normal, around the industry mean (4.941). AXON has a moderately high P/E Ratio (155.097) as compared to the industry average of (17.156). Projected Growth (PEG Ratio) (1.949) is also within normal values, averaging (2.564). Dividend Yield (0.000) settles around the average of (0.061) among similar stocks. P/S Ratio (12.034) is also within normal values, averaging (18.330).
PGEN sees MACD Histogram just turned negative
PGEN saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on October 06, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 55 instances where the indicator turned negative. In 48 of the 55 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 87%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 12, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on PGEN as a result. In 83 of 97 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 86%.
PGEN moved below its 50-day moving average on October 15, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PGEN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 84%.
Bullish Trend Analysis
The RSI Indicator entered the oversold zone -- be on the watch for PGEN's price rising or consolidating in the future. That's also the time to consider buying the stock or exploring call options.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 7 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +3.58% 3-day Advance, the price is estimated to grow further. Considering data from situations where PGEN advanced for three days, in 203 of 237 cases, the price rose further within the following month. The odds of a continued upward trend are 86%.
PGEN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In 163 of 177 cases where PGEN Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 90%.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 22 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 37 (best 1 - 100 worst), indicating steady price growth. PGEN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Profit vs. Risk Rating rating for this company is 86 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PGEN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.
The Tickeron Valuation Rating of 93 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: PGEN's P/B Ratio (54.721) is slightly higher than the industry average of (2.835). P/E Ratio (-6.224) is within average values for comparable stocks, (-0.607). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (135.264) among similar stocks. P/S Ratio (32.258) is also within normal values, averaging (438.009).
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
AXON | PGEN | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 50 | 50 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 92 Overvalued | 93 Overvalued | |
PROFIT vs RISK RATING 1..100 | 72 | 86 | |
SMR RATING 1..100 | 81 | 100 | |
PRICE GROWTH RATING 1..100 | 64 | 37 | |
P/E GROWTH RATING 1..100 | 41 | 22 | |
SEASONALITY SCORE 1..100 | 85 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
AXON's Valuation (92) in the Biotechnology industry is in the same range as PGEN (93) in the null industry. This means that AXON’s stock grew similarly to PGEN’s over the last 12 months.
AXON's Profit vs Risk Rating (72) in the Biotechnology industry is in the same range as PGEN (86) in the null industry. This means that AXON’s stock grew similarly to PGEN’s over the last 12 months.
AXON's SMR Rating (81) in the Biotechnology industry is in the same range as PGEN (100) in the null industry. This means that AXON’s stock grew similarly to PGEN’s over the last 12 months.
PGEN's Price Growth Rating (37) in the null industry is in the same range as AXON (64) in the Biotechnology industry. This means that PGEN’s stock grew similarly to AXON’s over the last 12 months.
PGEN's P/E Growth Rating (22) in the null industry is in the same range as AXON (41) in the Biotechnology industry. This means that PGEN’s stock grew similarly to AXON’s over the last 12 months.
| AXON | PGEN | |
|---|---|---|
| RSI ODDS (%) | 4 days ago 89% | 4 days ago 90% |
| Stochastic ODDS (%) | 4 days ago 84% | 4 days ago 86% |
| Momentum ODDS (%) | N/A | 4 days ago 86% |
| MACD ODDS (%) | 4 days ago 71% | 4 days ago 87% |
| TrendWeek ODDS (%) | 4 days ago 69% | 4 days ago 85% |
| TrendMonth ODDS (%) | 4 days ago 71% | 4 days ago 87% |
| Advances ODDS (%) | 11 days ago 74% | 11 days ago 86% |
| Declines ODDS (%) | 6 days ago 70% | 4 days ago 84% |
| BollingerBands ODDS (%) | 4 days ago 79% | 4 days ago 90% |
| Aroon ODDS (%) | 4 days ago 58% | 4 days ago 90% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
AXON’s FA Score shows that 0 FA rating(s) are green while PGEN’s FA Score has 0 green FA rating(s).
- AXON’s FA Score: 0 green, 5 red.
- PGEN’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
AXON’s TA Score shows that 5 TA indicator(s) are bullish while PGEN’s TA Score has 5 bullish TA indicator(s).
- AXON’s TA Score: 5 bullish, 2 bearish.
- PGEN’s TA Score: 5 bullish, 4 bearish.
Price Growth
AXON (@Aerospace & Defense) experienced а -7.56% price change this week, while PGEN (@Biotechnology) price change was -13.05% for the same time period.
The average weekly price growth across all stocks in the @Aerospace & Defense industry was -4.79%. For the same industry, the average monthly price growth was -13.69%, and the average quarterly price growth was -19.49%.
The average weekly price growth across all stocks in the @Biotechnology industry was -7.86%. For the same industry, the average monthly price growth was -18.66%, and the average quarterly price growth was -19.56%.
Reported Earning Dates
AXON is expected to report earnings on Nov 10, 2026.
PGEN is expected to report earnings on Nov 05, 2026.
Industries' Descriptions
@Aerospace & Defense (-4.79% weekly)Aerospace & Defense is one of largest industries in the U.S., mainly comprising the following areas: commercial airliners, military aircraft, missiles, space, and general aviation. Focused heavily on research & development, it is also one of the fastest growing industries. Military aircraft has the largest market share in the industry’s sales, followed by space systems, civil aircraft, and missiles. Aerospace exports, directly and indirectly, support more jobs than the export of any other commodity, according to a study by the U.S. Department of Commerce. Boeing Company, Lockheed Martin Corporation and General Electric Company are some of the most prominent players in this space.
@Biotechnology (-7.86% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| ECON | 33.18 | 0.26 | +0.79% |
| Columbia Research Enhanced Emerging Economies ETF (ECON) | |||
| UCIB | 38.36 | N/A | N/A |
| ETRACS CMCI Total Return ETN Series B (UCIB) | |||
| KLIP | 21.90 | N/A | N/A |
| KraneShares KWEB Covered Call Strategy ETF (KLIP) | |||
| FDRX | 22.20 | N/A | N/A |
| Founder-Led 2X Daily ETF | |||
| RWK | 142.27 | -0.27 | -0.19% |
| Invesco S&P MidCap 400 Revenue ETF (RWK) | |||